HK1246807A1 - Mk2抑制剂肽的制剂 - Google Patents
Mk2抑制剂肽的制剂 Download PDFInfo
- Publication number
- HK1246807A1 HK1246807A1 HK18106201.2A HK18106201A HK1246807A1 HK 1246807 A1 HK1246807 A1 HK 1246807A1 HK 18106201 A HK18106201 A HK 18106201A HK 1246807 A1 HK1246807 A1 HK 1246807A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- formulation
- polypeptide
- inhibitor peptides
- trehalose
- bioavailability
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101190P | 2015-01-08 | 2015-01-08 | |
| US201562101190P | 2015-01-08 | ||
| PCT/US2016/012650 WO2016112292A1 (en) | 2015-01-08 | 2016-01-08 | Formulation of mk2 inhibitor peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1246807A1 true HK1246807A1 (zh) | 2018-09-14 |
Family
ID=56356475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18106201.2A HK1246807A1 (zh) | 2015-01-08 | 2016-01-08 | Mk2抑制剂肽的制剂 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10087225B2 (https=) |
| EP (1) | EP3242886A4 (https=) |
| JP (1) | JP2018502860A (https=) |
| KR (1) | KR20170102900A (https=) |
| CN (1) | CN107406489A (https=) |
| AU (1) | AU2016205125A1 (https=) |
| BR (1) | BR112017014737A2 (https=) |
| CA (1) | CA2972916A1 (https=) |
| HK (1) | HK1246807A1 (https=) |
| MX (1) | MX2017008994A (https=) |
| RU (1) | RU2017128077A (https=) |
| SG (1) | SG11201705559RA (https=) |
| WO (1) | WO2016112292A1 (https=) |
| ZA (1) | ZA201704495B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62017B1 (sr) | 2014-09-17 | 2021-07-30 | Celgene Car Llc | Mk2 inhibitori i njihova upotreba |
| US10882867B2 (en) | 2017-03-16 | 2021-01-05 | Celgene Car Llc | Forms and compositions of a MK2 inhibitor |
| WO2019176618A1 (ja) | 2018-03-13 | 2019-09-19 | 株式会社Adeka | 非水電解質二次電池 |
| US20210322310A1 (en) * | 2020-04-16 | 2021-10-21 | Cai Gu Huang | Inhalable Formulation of a Solution Containing Tiotropium Bromide |
| CN111647088B (zh) * | 2020-06-29 | 2023-05-02 | 东北师范大学 | 细胞渗透短肽tat-hns-3及对炎性疾病的应用 |
| MX2024008704A (es) | 2022-01-14 | 2024-07-22 | Shanghai Hansoh Biomedical Co Ltd | Derivado policiclico que contiene piridina, y metodo de preparacion de este y uso de este. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| DK172541B1 (da) | 1982-10-08 | 1998-12-07 | Glaxo Group Ltd | Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet |
| DE3682457D1 (de) | 1985-07-30 | 1991-12-19 | Glaxo Group Ltd | Geraet zur verabreichung von medikamenten an patienten. |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US20080176790A1 (en) * | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
| DK2617431T3 (en) | 2007-01-10 | 2017-07-10 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and applications therefor |
| WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| CN102256613B (zh) * | 2008-10-20 | 2014-09-10 | 莫伊莱麦屈克斯公司 | 用于治疗或者预防粘连的多肽 |
| EP2378875B1 (en) * | 2008-12-10 | 2018-05-30 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US9890195B2 (en) | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| US20130115256A1 (en) | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
| US9890200B2 (en) * | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| KR101862291B1 (ko) * | 2011-04-12 | 2018-05-29 | 모레 매트릭스 인코포레이티드 | 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법 |
| US20140072613A1 (en) | 2012-09-10 | 2014-03-13 | Cynthia Lander | Compositions and Methods for Treating Cutaneous Scarring |
| US9102015B2 (en) * | 2013-03-14 | 2015-08-11 | Siemens Energy, Inc | Method and apparatus for fabrication and repair of thermal barriers |
| WO2014169256A2 (en) * | 2013-04-11 | 2014-10-16 | Vanderbilt University | Polyplexes |
-
2016
- 2016-01-08 WO PCT/US2016/012650 patent/WO2016112292A1/en not_active Ceased
- 2016-01-08 US US14/991,531 patent/US10087225B2/en not_active Expired - Fee Related
- 2016-01-08 CN CN201680005237.6A patent/CN107406489A/zh active Pending
- 2016-01-08 HK HK18106201.2A patent/HK1246807A1/zh unknown
- 2016-01-08 MX MX2017008994A patent/MX2017008994A/es unknown
- 2016-01-08 SG SG11201705559RA patent/SG11201705559RA/en unknown
- 2016-01-08 JP JP2017536526A patent/JP2018502860A/ja active Pending
- 2016-01-08 AU AU2016205125A patent/AU2016205125A1/en not_active Abandoned
- 2016-01-08 EP EP16735478.6A patent/EP3242886A4/en not_active Withdrawn
- 2016-01-08 KR KR1020177021042A patent/KR20170102900A/ko not_active Withdrawn
- 2016-01-08 RU RU2017128077A patent/RU2017128077A/ru not_active Application Discontinuation
- 2016-01-08 BR BR112017014737A patent/BR112017014737A2/pt not_active Application Discontinuation
- 2016-01-08 CA CA2972916A patent/CA2972916A1/en not_active Abandoned
-
2017
- 2017-07-03 ZA ZA2017/04495A patent/ZA201704495B/en unknown
-
2018
- 2018-08-21 US US16/106,504 patent/US20190031730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3242886A1 (en) | 2017-11-15 |
| RU2017128077A (ru) | 2019-02-08 |
| AU2016205125A2 (en) | 2017-10-19 |
| KR20170102900A (ko) | 2017-09-12 |
| US20190031730A1 (en) | 2019-01-31 |
| JP2018502860A (ja) | 2018-02-01 |
| EP3242886A4 (en) | 2018-08-29 |
| MX2017008994A (es) | 2018-09-18 |
| US10087225B2 (en) | 2018-10-02 |
| SG11201705559RA (en) | 2017-08-30 |
| US20160200782A1 (en) | 2016-07-14 |
| BR112017014737A2 (pt) | 2018-01-16 |
| ZA201704495B (en) | 2019-01-30 |
| CA2972916A1 (en) | 2016-07-14 |
| WO2016112292A1 (en) | 2016-07-14 |
| RU2017128077A3 (https=) | 2019-09-30 |
| CN107406489A (zh) | 2017-11-28 |
| AU2016205125A1 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1246807A1 (zh) | Mk2抑制剂肽的制剂 | |
| ZA201900367B (en) | Formulation of a peptide vaccine | |
| MX2018013215A (es) | Composicion farmaceutica. | |
| EP4389898A3 (en) | T cell receptors | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| ES2673556T3 (es) | Vacunas para el VHS-2 | |
| WO2016118014A3 (en) | Anti-senescence compounds and uses thereof | |
| PH12018502714A1 (en) | Nicotine particles and compositions | |
| WO2014139476A8 (zh) | Rsv融合蛋白的表位以及识别其的抗体 | |
| MY200841A (en) | Influenza Virus Vaccines and Uses Thereof | |
| MX2019006943A (es) | Polipéptidos para manejo de infecciones virales. | |
| MX2018014023A (es) | Compuestos de citocina inhibidora de macrofagos 1 (mic-1) y uso de estos. | |
| EP4653537A3 (en) | Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function | |
| SG10201809228RA (en) | Lyophilized formulation of hgf | |
| WO2015106224A3 (en) | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof | |
| CN110809579A (zh) | 多肽的药学可接受的盐及其应用 | |
| WO2011123858A3 (en) | Ccn3 peptides and analogs thereof for therapeutic use | |
| MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. | |
| MX2018002616A (es) | Proteina de fusion. | |
| WO2012162637A3 (en) | Vaccine adjuvants from self-assembling peptides | |
| WO2016172269A3 (en) | Insulin analogs having shortened b chain peptides and associated methods | |
| WO2015041924A8 (en) | Recombinant respiratory syncytial virus (rsv) and vaccines | |
| MX2019013874A (es) | Peptidos y sus usos como agentes antivirales. | |
| JP2018529625A5 (https=) | ||
| WO2016197042A8 (en) | Modified or targeted release formulations of linaclotide |